Previous 10 | Next 10 |
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5 th - 8 th , 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Fall Harvest - Best...
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation. In the past severa...
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17 th Annual Meeting of the Oligonucleotide Therapeutics Society N...
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice Studies indicate Duet’s bifunctional oligonucleotid...
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet Therapeutic...
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that Duet Therapeutic...
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a s...
Gainers: FEIM +24.6%. LILM +6.5%. CNXC +6.0%. SCPS +5.5%. SGMS +4.3%. Losers: DOCU -6.1%. IMRX -5.0%. HIBB -1.7%. CRVS -1.6%. VG -1.5%. For further details see: FEIM, LILM, DOCU and IMRX among after hours movers
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will be presenting...
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors Presentations to cover CpG-STAT3siRNA (DUET-01) and CpG-STAT3ASO (DUET-02) NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sc...
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
Scopus BioPharma Inc. Website:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...